Skymab chaired scientific sessions dedicated to next-generation GPCR therapeutics and ADC innovation, contributing to discussions on emerging technologies addressing difficult-to-drug targets and precision oncology.
Skymab chaired scientific sessions dedicated to next-generation GPCR therapeutics and ADC innovation, contributing to discussions on emerging technologies addressing difficult-to-drug targets and precision oncology.